SH3 and cysteine rich domain 2Genealiases: 24b2 · 24b2/STAC2
Q-omics provides the consensus-scored STAC2 profile across patient tissues and cancer cell-line models. STAC2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, STAC2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, STAC2 RNA expression shows 12,515 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, KIRC, and TGCT as cancer lineages where STAC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAC2 survival associations across molecular data types. STAC2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAC2 RNA expression–survival associations across cancer types. High STAC2 expression shows unfavorable associations in LUSC, KIRP, UCEC, ACC, OV and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for STAC2 RNA expression.
This table summarizes STAC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STAC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAC2 shows lower tumor expression in KIRC, HNSC, KIRP, BRCA and COAD and higher tumor expression in KICH. The KIRC box plot shows higher STAC2 RNA expression in normal versus tumor tissue (log2 FC = −2.929, t-test p < 0.001).
This table shows molecular features associated with STAC2 in patient tissues and cancer cell lines. In patient samples, STAC2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STAC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
